

ADCs First to Cervix Cancer and Here to Stay: Understanding Provider and Patient Perspectives

An Industry Supported Symposium during the 2024 SGO Annual Meeting on Women's Cancer®

Sunday, March 17, 2024
San Diego, California

*This symposium was developed by The GOG Foundation, Inc.
in partnership with Seagen, Inc. and Genmab*



Welcome and Introductions

Bhavana Pothuri, MD

NYU Langone, Perlmutter Cancer Center
New York, NY



THANK YOU

To Our Sponsor For Today's Industry Supported Symposium



Our Expert Panel



Bhavana Pothuri, MD
NYU Langone,
Perlmutter Cancer Center
New York, NY



Leslie Randall, MD, MAS
Virginia Commonwealth
University Richmond, VA



Susana Campos, MD, MPH
Dana Farber Cancer Institute
Boston, MA



Kathleen Lutz, NP
NYU Langone,
Perlmutter Cancer Center
New York, NY



Andrea Kinloch
Patient Advocate
Los Angeles, CA

Disclosures

Faculty	
Bhavana Pothuri, MD	Clinical Trial Grants (to Institution): AstraZeneca, Celsion, ImmunoGen, Clovis Oncology, Genentech, GSK, I-Mab, ImmunoGen, Incyte, Karyopharm, Merck, Mersana, Seagen, Sutro, Toray Consultant: AstraZeneca, Eisai, GSK, I-Mab, Merck, Mersana, Seagen, Sutro
Leslie Randall, MD, MAS	Consultant: AstraZeneca, Clovis Oncology, GSK, Immunogen, Seagen
Susana Campos, MD, MPH	Honorarium: Merck, Eisai, AstraZeneca, Seagen
Kathleen Lutz, NP	Paid Advisory Board Member: AstraZeneca, Merck Eisai
Andrea Kinloch	None

Agenda

Topic	Presenter
Welcome and Introduction	Bhavana Pothuri, MD NYU Langone, Perlmutter Cancer Center, New York, NY
Introduction to ADCs, Understanding the Mechanism of Action with a Case Presentation	Susana Campos, MD, MPH Dana Farber Cancer Institute, Boston, MA
TV 301 Phase III, PRO Data and Adverse Events	Dr. Leslie Randall, MD, MAS Virginia Commonwealth University, Richmond, VA
Education, Adherence and Symptom Management in Patients with Cervix Cancer Treated with ADC Therapy	Kathleen Lutz, NP NYU Langone, Perlmutter Cancer Center, New York, NY
The Patient Perspective on Cervix Cancer and Treatment of Recurrence	Andrea Kinloch Patient Advocate, Los Angeles, CA
Panel Discussion and Q&A	All Faculty
Closing Comments	Bhavana Pothuri, MD NYU Langone, Perlmutter Cancer Center, New York, NY

Learning Objectives

Upon completion of this activity, learners will:

- Review the current landscape for the treatment of recurrent cervix cancer based on pivotal clinical trial data and insights from 2023
- Understand the role of ADC in cervix cancer, and how to educate patients on this novel treatment option
- Review and incorporate updated data in treatment decision making through case-based learning
- Understand the patient perspective with respect to receiving treatments in recurrent cervix cancer